Of note, these therapies are also recommended for individuals with Dravet syndrome who do not have known SCN1A variants (i.e. in those with other monogenic causes of Dravet syndrome, or in those in whom a genetic cause has not been identified); AAV9 = adeno-associated viral vector serotype 9; ASM = antiseizure medication; GOF = gain of function; LOF = loss of function; NGS = next generation sequencing; RCT = randomised controlled trial; SUDEP = sudden unexpected death in epilepsy. This evidence concerns the gene SCN1A and epilepsy.